Personalised medicine in veterinary oncology: One to cure just one

Veterinary Journal

Volumn 205, Issue 2, 2015, Pages 128-135

  Klopfleisch, R ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Biomarker; Carcinogenesis; Next generation sequencing; Oncology; Personalised medicine

Indexed keywords

IMATINIB; MASITINIB; MESSENGER RNA; PROTEOME; TUMOR MARKER;

B CELL LYMPHOMA; BIOINFORMATICS; BREAST TUMOR; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; GENE EXPRESSION; GENOME; GENOTYPE; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MICROARRAY ANALYSIS; MINIMAL RESIDUAL DISEASE; NEXT GENERATION SEQUENCING; NONHUMAN; ONCOLOGY; PERSONALIZED MEDICINE; PHENOTYPE; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; TUMOR GENE; VETERINARY MEDICINE; WESTERN BLOTTING; ANIMAL; HIGH THROUGHPUT SEQUENCING; NEOPLASMS; TRENDS; VETERINARY;

ANIMALS; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; NEOPLASMS; PRECISION MEDICINE; PROTEOMICS;

EID: 84937520690     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2015.01.004     Document Type: Review

References (74)

1. Anderson K., Lutz C., van Delft F.W., Bateman C.M., Guo Y., Colman S.M., Kempski H., Moorman A.V., Titley I., Swansbury J., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469:356-361.
2. Aresu L., Arico A., Comazzi S., Gelain M.E., Riondato F., Mortarino M., Morello E., Stefanello D., Castagnaro M. VEGF and MMP-9: Biomarkers for canine lymphoma. Veterinary and Comparative Oncology 2014, 12:29-36.
3. Atherton M.J., Braceland M., Fontaine S., Waterston M.M., Burchmore R.J., Eadie S., Eckersall P.D., Morris J.S. Changes in the serum proteome of canine lymphoma identified by electrophoresis and mass spectrometry. The Veterinary Journal 2013, 196:320-324.
4. Burrell R.A., McGranahan N., Bartek J., Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013, 501:338-345.
5. Cahill D.P., Kinzler K.W., Vogelstein B., Lengauer C. Genetic instability and darwinian selection in tumours. Trends in Cell Biology 1999, 9:M57-M60.
6. Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
7. Cancer Genome Atlas Research Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
8. Cancer Genome Atlas Research Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
9. Weinstein J.N., Collisson E.A., Mills G.B., Shaw K.R., Ozenberger B.A., Ellrott K., Shmulevich I., Sander C., Stuart J.M. The cancer genome Atlas Pan-cancer analysis project. Nature Genetics 2013, 45:1113-1120. Cancer Genome Atlas Research Network.
10. Chen E.I., Yates J.R. Cancer proteomics by quantitative shotgun proteomics. Molecular Oncology 2007, 1:144-159.
11. da Costa A., Oliveira J.T., Gartner F., Kohn B., Gruber A.D., Klopfleisch R. Potential markers for detection of circulating canine mammary tumor cells in the peripheral blood. The Veterinary Journal 2011, 190:165-168.
12. da Costa A., Lenze D., Hummel M., Kohn B., Gruber A.D., Klopfleisch R. Identification of six potential markers for the detection of circulating canine mammary tumour cells in the peripheral blood identified by microarray analysis. Journal of Comparative Pathology 2012, 146:143-151.
13. da Costa A., Kohn B., Gruber A.D., Klopfleisch R. Multiple RT-PCR markers for the detection of circulating tumour cells of metastatic canine mammary tumours. The Veterinary Journal 2013, 196:34-39.
14. de Freitas Campos C., Cole N., Van Dyk D., Walsh B.J., Diakos P., Almeida D., Torrecilhas A., Laus J.L., Willcox M.D. Proteomic analysis of dog tears for potential cancer markers. Research in Veterinary Science 2008, 85:349-352.
15. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nature Reviews. Cancer 2004, 4:143-153.
16. Frantz A.M., Sarver A.L., Ito D., Phang T.L., Karimpour-Fard A., Scott M.C., Valli V.E., Lindblad-Toh K., Burgess K.E., Husbands B.D., et al. Molecular profiling reveals prognostically significant subtypes of canine lymphoma. Veterinary Pathology 2013, 50:693-703.
17. Gaines P.J., Powell T.D., Walmsley S.J., Estredge K.L., Wisnewski N., Stinchcomb D.T., Withrow S.J., Lana S.E. Identification of serum biomarkers for canine B-cell lymphoma by use of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry. American Journal of Veterinary Research 2007, 68:405-410.
18. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine 2012, 366:883-892.
19. Gorges T.M., Pantel K. Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunology, Immunotherapy 2013, 62:931-939.
20. Govindan R., Ding L., Griffith M., Subramanian J., Dees N.D., Kanchi K.L., Maher C.A., Fulton R., Fulton L., Wallis J., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012, 150:1121-1134.
21. Hahn K.A., Ogilvie G., Rusk T., Devauchelle P., Leblanc A., Legendre A., Powers B., Leventhal P.S., Kinet J.P., Palmerini F., et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 2008, 22:1301-1309.
22. Hahn K.A., Legendre A.M., Shaw N.G., Phillips B., Ogilvie G.K., Prescott D.M., Atwater S.W., Carreras J.K., Lana S.E., Ladue T., et al. Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. American Journal of Veterinary Research 2010, 71:1354-1361.
23. Hoglund M., Gisselsson D., Sall T., Mitelman F. Coping with complexity. multivariate analysis of tumor karyotypes. Cancer Genetics and Cytogenetics 2002, 135:103-109.
24. Honda K., Ono M., Shitashige M., Masuda M., Kamita M., Miura N., Yamada T. Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine. Japanese Journal of Clinical Oncology 2013, 43:103-109.
25. Isotani M., Tamura K., Yagihara H., Hikosaka M., Ono K., Washizu T., Bonkobara M. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. Veterinary Immunology and Immunopathology 2006, 114:168-172.
26. Isotani M., Ishida N., Tominaga M., Tamura K., Yagihara H., Ochi S., Kato R., Kobayashi T., Fujita M., Fujino Y., et al. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. Journal of Veterinary Internal Medicine 2008, 22:985-988.
27. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
28. Jones S., Chen W.D., Parmigiani G., Diehl F., Beerenwinkel N., Antal T., Traulsen A., Nowak M.A., Siegel C., Velculescu V.E., et al. Comparative lesion sequencing provides insights into tumor evolution. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:4283-4288.
29. Kalia M. Personalized oncology: Recent advances and future challenges. Metabolism: Clinical and Experimental 2013, 62:S11-S14.
30. Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., Xie M., Zhang Q., McMichael J.F., Wyczalkowski M.A., et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
31. Keats J.J., Chesi M., Egan J.B., Garbitt V.M., Palmer S.E., Braggio E., Van Wier S., Blackburn P.R., Baker A.S., Dispenzieri A., et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012, 120:1067-1076.
32. Kelly C.M., Power D.G., Lichtman S.M. Targeted therapy in older patients with solid tumors. Journal of Clinical Oncology 2014, 32:2635-2646.
33. Klopfleisch R. Personalized medicine in veterinary oncology: Minimal residual disease and circulating tumour cells in dogs. The Veterinary Journal 2013, 195:263-264.
34. Klopfleisch R., Gruber A.D. Transcriptome and proteome research in veterinary science: What is possible and what questions can be asked?. The Scientific World Journal 2012, 2012:254962.
35. Klopfleisch R., Klose P., Gruber A.D. The combined expression pattern of BMP2, LTBP4, and DERL1 discriminates malignant from benign canine mammary tumors. Veterinary Pathology 2010, 47:446-454.
36. Klopfleisch R., Klose P., Weise C., Bondzio A., Multhaup G., Einspanier R., Gruber A.D. Proteome of metastatic canine mammary carcinomas: Similarities to and differences from human breast cancer. Journal of Proteome Research 2010, 9:6380-6391.
37. Klopfleisch R., Lenze D., Hummel M., Gruber A.D. Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles. BMC Cancer 2010, 10:618.
38. Klopfleisch R., Lenze D., Hummel M., Gruber A.D. The metastatic cascade is reflected in the transcriptome of metastatic canine mammary carcinomas. The Veterinary Journal 2011, 190:236-243.
39. Klopfleisch R., Meyer A., Schlieben P., Bondzio A., Weise C., Lenze D., Hummel M., Einspanier R., Gruber A.D. Transcriptome and proteome analysis of tyrosine kinase inhibitor treated canine mast cell tumour cells identifies potentially kit signaling-dependent genes. BMC Veterinary Research 2012, 8:96.
40. Klose P., Weise C., Bondzio A., Multhaup G., Einspanier R., Gruber A.D., Klopfleisch R. Is there a malignant progression associated with a linear change in protein expression levels from normal canine mammary gland to metastatic mammary tumors?. Journal of Proteome Research 2011, 10:4405-4415.
41. Kobayashi M., Sugisaki O., Ishii N., Yamada O., Ito K., Kuroki S., Sasaki Y., Ono K., Washizu T., Bonkobara M. Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy. The Veterinary Journal 2012, 193:264-267.
42. Kreso A., O'Brien C.A., van Galen P., Gan O.I., Notta F., Brown A.M., Ng K., Ma J., Wienholds E., Dunant C., et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013, 339:543-548.
43. Landau D.A., Carter S.L., Stojanov P., McKenna A., Stevenson K., Lawrence M.S., Sougnez C., Stewart C., Sivachenko A., Wang L., et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013, 152:714-726.
44. Lawrence J., Saba C., Gogal R., Lamberth O., Vandenplas M.L., Hurley D.J., Dubreuil P., Hermine O., Dobbin K., Turek M. Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells. Veterinary and Comparative Oncology 2012, 10:143-154.
45. London C.A., Galli S.J., Yuuki T., Hu Z.Q., Helfand S.C., Geissler E.N. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Experimental Hematology 1999, 27:689-697.
46. Longley B.J., Tyrrell L., Lu S.Z., Ma Y.S., Langley K., Ding T.G., Duffy T., Jacobs P., Tang L.H., Modlin I. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nature Genetics 1996, 12:312-314.
47. Lynch M. Rate, molecular spectrum, and consequences of human mutation. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:961-968.
48. Mak K.S., Gainor J.F., Niemierko A., Oh K.S., Willers H., Choi N.C., Loeffler J.S., Sequist L.V., Shaw A.T., Shih H.A. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Neuro-Oncology 2014, 10.1093/neuonc/nou146.
49. Martinez P., Birkbak N.J., Gerlinger M., McGranahan N., Burrell R.A., Rowan A.J., Joshi T., Fisher R., Larkin J., Szallasi Z., et al. Parallel evolution of tumour subclones mimics diversity between tumours. The Journal of Pathology 2013, 230:356-364.
50. Marusyk A., Almendro V., Polyak K. Intra-tumour heterogeneity: A looking glass for cancer?. Nature Reviews Cancer 2012, 12:323-334.
51. McCaw D.L., Chan A.S., Stegner A.L., Mooney B., Bryan J.N., Turnquist S.E., Henry C.J., Alexander H., Alexander S. Proteomics of canine lymphoma identifies potential cancer-specific protein markers. Clinical Cancer Research 2007, 13:2496-2503.
52. Mobasheri A. Exploring the serum proteome in dogs: Setting the scene for the discovery of new biomarkers in canine lymphoma. The Veterinary Journal 2013, 196:286-287.
53. Mudaliar M.A., Haggart R.D., Miele G., Sellar G., Tan K.A., Goodlad J.R., Milne E., Vail D.M., Kurzman I., Crowther D., et al. Comparative gene expression profiling identifies common molecular signatures of NF-kappaB activation in canine and human diffuse large B cell lymphoma (DLBCL). PLoS ONE 2013, 8:e72591.
54. Nagata H., Worobec A.S., Oh C.K., Chowdhury B.A., Tannenbaum S., Suzuki Y., Metcalfe D.D. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:10560-10564.
55. Nakano Y., Kobayashi T., Oshima F., Fukazawa E., Yamagami T., Shiraishi Y., Takanosu M. Imatinib responsiveness in canine mast cell tumors carrying novel mutations of c-KIT exon 11. The Journal of Veterinary Medical Science 2014, 76:545-548.
56. Ratcliffe L., Mian S., Slater K., King H., Napolitano M., Aucoin D., Mobasheri A. Proteomic identification and profiling of canine lymphoma patients. Veterinary and Comparative Oncology 2009, 7:92-105.
57. Richards K.L., Motsinger-Reif A.A., Chen H.W., Fedoriw Y., Fan C., Nielsen D.M., Small G.W., Thomas R., Smith C., Dave S.S., et al. Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. Cancer Research 2013, 73:5029-5039.
58. Roberts K.G., Pei D., Campana D., Payne-Turner D., Li Y., Cheng C., Sandlund J.T., Jeha S., Easton J., Becksfort J., et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. Journal of Clinical Oncology 2014, 32:3012-3020.
59. Sato M., Yamzaki J., Goto-Koshino Y., Takahashi M., Fujino Y., Ohno K., Tsujimoto H. The prognostic significance of minimal residual disease in the early phases of chemotherapy in dogs with high-grade B-cell lymphoma. The Veterinary Journal 2013, 195:319-324.
60. Schleidgen S., Klingler C., Bertram T., Rogowski W.H., Marckmann G. What is personalized medicine: Sharpening a vague term based on a systematic literature review. BMC Medical Ethics 2013, 14:55.
61. Schlieben P., Meyer A., Weise C., Bondzio A., Einspanier R., Gruber A.D., Klopfleisch R. Differences in the proteome of high-grade versus low-grade canine cutaneous mast cell tumours. The Veterinary Journal 2012, 194:210-214.
62. Schlieben P., Meyer A., Weise C., Bondzio A., Gruber A.D., Klopfleisch R. Tandem duplication of KIT exon 11 influences the proteome of canine mast cell tumours. Journal of Comparative Pathology 2013, 148:318-322.
63. Smrkovski O.A., Essick L., Rohrbach B.W., Legendre A.M. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours. Veterinary and Comparative Oncology 2013.
64. Sottoriva A., Spiteri I., Shibata D., Curtis C., Tavare S. Single-molecule genomic data delineate patient-specific tumor profiles and cancer stem cell organization. Cancer Research 2013, 73:41-49.
65. Stephens P.J., Tarpey P.S., Davies H., Van Loo P., Greenman C., Wedge D.C., Nik-Zainal S., Martin S., Varela I., Bignell G.R., et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012, 486:400-404.
66. Uhlen M., Oksvold P., Fagerberg L., Lundberg E., Jonasson K., Forsberg M., Zwahlen M., Kampf C., Wester K., Hober S., et al. Towards a knowledge-based Human Protein Atlas. Nature Biotechnology 2010, 28:1248-1250.
67. Ulahannan D., Kovac M.B., Mulholland P.J., Cazier J.B., Tomlinson I. Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. British Journal of Cancer 2013, 109:827-835.
68. Varley K.E., Mutch D.G., Edmonston T.B., Goodfellow P.J., Mitra R.D. Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing. Nucleic Acids Research 2009, 37:4603-4612.
69. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
70. Webster J.D., Yuzbasiyan-Gurkan V., Miller R.A., Kaneene J.B., Kiupel M. Cellular proliferation in canine cutaneous mast cell tumors: Associations with c-KIT and its role in prognostication. Veterinary Pathology 2007, 44:298-308.
71. Yamada O., Kobayashi M., Sugisaki O., Ishii N., Ito K., Kuroki S., Sasaki Y., Isotani M., Ono K., Washizu T., et al. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation. Veterinary Immunology and Immunopathology 2011, 142:101-106.
72. Yamada O., Ozaki K., Furukawa T., Machida M., Wang Y.H., Motoji T., Mitsuishi T., Akiyama M., Yamada H., Kawauchi K., et al. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. Cellular Signalling 2011, 23:1119-1127.
73. Zamani-Ahmadmahmudi M., Nassiri S.M., Rahbarghazi R. Serological proteome analysis of dogs with breast cancer unveils common serum biomarkers with human counterparts. Electrophoresis 2014, 35:901-910.
74. Zandvliet M., Teske E., Chapuis T., Fink-Gremmels J., Schrickx J.A. Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein. Journal of Veterinary Pharmacology and Therapeutics 2013, 36:583-587.